Physician profile
Lisa Black
NPI 1851484307
$4,580.22
in general payments reported to CMS, 2019-2025
39 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $1,421 · 2021: $1,038 · 2022: $43.19 · 2024: $338 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $688.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $392.57 | 2019-2021 | |
| Galderma Laboratories, L.P. | $376.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.23 | 2019-2021 | |
| Lilly USA, LLC | $339.90 | 2019-2025 | Mounjaro |
| Allergan, INC. | $301.41 | 2019-2020 | |
| Abbvie INC. | $276.57 | 2019-2024 | |
| Amgen INC. | $265.41 | 2019-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $231.21 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.27 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $142.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $137.65 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $112.50 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $73.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $65.13 | 2019-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.